New-generation cancer drugs, often referred to as “smart drugs,” may play an important role in the treatment of certain cancer patients. However, these drugs are usually expensive, and not every drug is automatically covered by the Turkish Social Security Institution, known as SGK. For this reason, many patients file lawsuits to have the cost of these drugs covered or reimbursed.

These cases are commonly known in practice as smart drug lawsuits or SGK drug reimbursement cases. They may involve requests for interim injunctions, reimbursement of previously paid drug costs, or continued coverage of the drug during treatment.

Recent Court of Cassation decisions show that these lawsuits now require a more detailed medical and legal assessment. A doctor’s recommendation alone may no longer be sufficient. Courts are expected to examine whether the drug is scientifically suitable for the specific patient, whether it is medically necessary, whether it provides meaningful and continuous benefit, and whether the relevant SGK reimbursement criteria are met.

1. What Is a Smart Drug Lawsuit?

A smart drug lawsuit is a legal action filed to request SGK coverage or reimbursement for a high-cost drug, usually used in cancer treatment.

The patient may claim that the drug is medically necessary, that alternative treatments are insufficient, and that the cost should be covered by SGK. In some cases, the patient seeks payment of the drug cost during ongoing treatment. In other cases, the patient has already purchased the drug and seeks reimbursement of the amount paid.

These cases frequently involve immunotherapy drugs, targeted therapies, biological agents and other high-cost cancer treatments.

2. Why May SGK Refuse to Pay for a Smart Drug?

SGK pays for medicines according to specific rules. The fact that a drug is licensed in Turkey, approved by a foreign authority, or prescribed by a doctor does not automatically mean that SGK must cover its cost.

One of the main issues is whether the drug is included in the relevant reimbursement rules. Even if a drug is included, SGK may cover it only under specific conditions. These conditions may relate to the type of cancer, disease stage, biomarker status, previous treatments, specialist reports or treatment line.

For this reason, an SGK refusal does not always mean that the drug is medically ineffective. The refusal may be based on reimbursement rules, missing documents, failure to meet technical criteria or lack of patient-specific medical justification.

3. What Has Changed in the Recent Court Approach?

The recent approach of the Court of Cassation indicates a stricter evidentiary standard in smart drug cases. Courts should not rely solely on the fact that the patient has cancer or that a physician recommended the drug.

The court may examine whether the drug is truly necessary for the patient, whether its use is supported by scientific data, whether it is appropriate for the patient’s cancer type and stage, and whether it provides a real therapeutic benefit compared to available alternatives.

This means that smart drug lawsuits should be prepared on a stronger medical basis. Legal arguments must be supported by detailed medical records, expert opinions and patient-specific scientific evidence.

4. Is Marketing Authorization Enough?

No. The fact that a drug is licensed or accepted in medical practice is important, but it is not always enough for SGK reimbursement.

The court may also examine whether the patient meets the conditions for using that drug. For example, if the drug is effective only for a certain cancer type, disease stage or genetic marker, the patient’s medical records must show that these conditions are present.

Therefore, in a smart drug lawsuit, it is not enough to argue that the drug is approved. It must also be shown that the drug is suitable and necessary for the specific patient.

5. Why Are SGK Reimbursement Rules Important?

SGK reimbursement rules determine which drugs are covered and under what conditions. In smart drug cases, one of the first questions is whether the drug was covered under the applicable rules at the time of application.

If the drug is covered, the patient must show that the required conditions are met. If the drug is not covered, or was not covered at the relevant time, the patient must provide stronger medical justification.

In such cases, issues such as medical necessity, life-saving importance, lack of effective alternatives and sustained benefit become more important.

6. Patient-Specific Scientific Suitability

Smart drugs do not produce the same result in every patient. A drug may be effective for one cancer type or subgroup, but this does not mean that it is suitable for all patients with the same general diagnosis.

For this reason, the patient’s cancer type, disease stage, previous treatments, genetic test results, biomarker status, general condition and expected benefit from the drug must be assessed together.

Biomarkers and genetic indicators such as PD-L1, EGFR, ALK, BRAF, HER2, MSI or NTRK may be relevant in certain cancer treatments. If such tests exist, they should be included in the case file.

7. Temporary Benefit vs. Continuous Effectiveness

One of the important issues in recent decisions is the distinction between temporary benefit and meaningful therapeutic effect.

A drug may provide short-term relief, temporary disease control or limited improvement in quality of life. However, this may not always be sufficient for reimbursement.

The court may examine whether the drug provides a clear, continuous and scientifically explainable benefit for the patient. Imaging results, tumor response, disease progression, treatment duration and expert oncology opinions may be important in this assessment.

8. Clinical Studies and Medical Evidence

In smart drug reimbursement cases, the scientific background of the drug may also be examined. Courts may consider whether the drug has been tested in clinical studies, for which patient groups its effectiveness has been shown, and whether there are strong Phase 3 or Phase 4 data.

This assessment helps determine whether the drug is experimental, widely accepted in medical practice, or a reasonable treatment option for the specific patient.

Therefore, the case should not rely only on a prescription or a short physician note. Scientific literature, indication information, clinical data and specialist reports may all be relevant.

9. Importance of Expert Reports

Expert reports are often decisive in smart drug lawsuits. However, general and abstract statements may not be enough.

An expert report should ideally address questions such as:

• What is the patient’s cancer type and stage?
• Is the drug suitable for this type of cancer?
• Do the patient’s genetic or biological characteristics support the use of the drug?
• Have standard treatments already been tried?
• Are SGK-covered alternatives sufficient?
• Does the drug offer a meaningful advantage over available treatments?
• Is the expected benefit temporary or continuous?
• Is the drug medically necessary?
• Does the drug have life-saving importance for the patient?
• Is the benefit-risk balance medically acceptable?

For this reason, the medical file must be prepared carefully before filing the lawsuit.

10. Are Interim Injunctions Still Possible?

In smart drug cases, patients often need access to the drug before the final judgment. Cancer treatment is time-sensitive, and delay may cause serious and irreversible harm. Therefore, an interim injunction may be requested when filing the lawsuit.

However, recent developments show that interim injunction requests also require stronger documentation. The court may examine whether the patient urgently needs the drug, whether available treatments are insufficient and whether the drug is scientifically suitable for the patient.

An interim injunction request should not be based only on the argument that the patient has cancer and the drug is expensive. The medical history, previous treatments, genetic tests, expert opinions and necessity of the drug should be clearly documented.

11. Can the Patient Claim Reimbursement After Paying for the Drug?

Yes. If the patient has already purchased the drug, reimbursement may be claimed from SGK. However, the patient must prove more than the fact that the drug was purchased and used.

The case should show that the drug was medically necessary, that alternative treatments were insufficient, that the drug was scientifically suitable for the patient and that it provided a meaningful therapeutic benefit.

Invoices are important, but they are not enough by themselves. Treatment records, specialist reports, genetic tests, imaging results and medical response after using the drug should also be submitted.

12. Application to SGK Before Filing a Lawsuit

Before filing a lawsuit, it is generally important to apply to SGK. The application should clearly explain why the drug is necessary, the patient’s medical condition, previous treatments and the expected benefit.

The application may include:

• oncology specialist report,
• medical board report,
• pathology report,
• genetic test or biomarker results,
• PET/CT and other imaging reports,
• records of previous treatments,
• prescription for the requested drug,
• medical justification for the drug,
• foreign drug use approval, if applicable,
• invoices and payment documents, if reimbursement is requested.

If SGK rejects the application or does not respond within the relevant period, legal action may be considered.

13. Important Documents in Smart Drug Cases

Incomplete documentation may negatively affect the case. Therefore, the file should be prepared carefully from both medical and legal perspectives.

Important documents may include:

• cancer diagnosis reports,
• documents showing the stage of disease,
• pathology and molecular pathology reports,
• genetic test results,
• oncology specialist opinion,
• medical board report,
• previous treatment records,
• chemotherapy, radiotherapy or surgery records,
• PET/CT, MRI and tomography results,
• prescription of the drug,
• drug use approval,
• SGK application documents,
• SGK rejection decision,
• invoices and payment records,
• reports showing response to the drug.

The number of documents is not the only issue. The documents must clearly explain why the drug is necessary for the specific patient.

14. What Do Recent Decisions Mean for Patients?

Recent Court of Cassation decisions do not mean that smart drug lawsuits can no longer be won. However, they show that these cases must be supported by stronger medical evidence.

A simple physician note or general treatment recommendation may not be sufficient. The patient must show, with concrete medical data, why the drug is necessary, why alternative treatments are inadequate and why the drug is expected to provide meaningful benefit.

For patients, the key point is that the case should be prepared before filing, not during the proceedings after objections arise.

15. What Do Recent Decisions Mean for SGK?

The recent approach also shows that courts take into account SGK’s role in managing public healthcare resources. Courts must balance the patient’s right to health and access to treatment with the sustainability of public reimbursement systems.

This does not mean that SGK may refuse payment in every case. Rather, courts are expected to examine whether the drug is truly necessary, scientifically supported and specifically beneficial for the patient.

16. What Should Be Checked Before Filing a Smart Drug Lawsuit?

Before filing a smart drug reimbursement case, the following questions should be assessed:

• Is the drug covered by SGK reimbursement rules?
• Does the patient meet the reimbursement criteria?
• Is the drug suitable for the patient’s cancer type and stage?
• Are genetic or biomarker results supportive?
• Have standard treatments been tried?
• Are SGK-covered alternatives insufficient?
• Can continuous and meaningful benefit be shown?
• Is the scientific basis of the drug strong?
• Are the medical reports sufficient?
• Is there enough evidence for an interim injunction?
• If the drug was purchased, are invoices and payment records complete?

Answering these questions before filing the case may reduce the risk of delay, rejection or procedural weakness.

Conclusion

Smart drug lawsuits are highly important for cancer patients, but they require careful legal and medical preparation. Recent Court of Cassation decisions show that a prescription or general physician recommendation may not be enough. Courts may examine patient-specific scientific suitability, medical necessity, life-saving importance, continuous effectiveness and SGK reimbursement criteria together.

If the patient seeks SGK coverage or reimbursement of smart drug costs, the case file should be supported by strong medical evidence. The patient’s cancer type, disease stage, genetic profile, previous treatments, response to the drug and lack of effective alternatives should be clearly demonstrated.

Success in smart drug cases depends not only on filing a lawsuit, but also on preparing the medical evidence and legal strategy properly from the beginning.